Plain-English translation of NCT06680661 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , a medication designed to reduce a serious complication called graft-versus-host disease (GVHD) that often occurs after stem cell transplants using umbilical cord blood. Patients with blood cancers like leukemia or lymphoma who don't have a matched adult bone marrow donor can benefit from cord blood transplants, but GVHD — where the new immune cells attack the patient's own body — happens in nearly half of these patients. This study is testing whether the medication can make these transplants safer by lowering rejection rates.
Umbilical cord blood is a lifesaving option for patients with blood cancers who can't find a matched adult donor, especially in Black, Asian, and Hispanic communities where matches are harder to find. However, the current approaches to prevent rejection are not working well enough, with serious rejection occurring in up to 24% of patients. This trial is exploring whether this medication can provide better protection without slowing down the immune system's recovery.
You likely qualify if…
You likely don't qualify if…
You would receive intensive chemotherapy and full-body radiation to prepare your body for the transplant, followed by infusion of two umbilical cord blood units. After transplant, you would receive the medication along with standard rejection-prevention drugs ( and ) to protect against graft-versus-host disease. You would have frequent hospital visits and blood tests to monitor your recovery, immune system health, and any side effects over the first several months and beyond.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States